Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 6 of 6 entries
View as:

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02914262 Org: User:
Start: 08/31/16 End: 01/31/17 Due: 01/31/18

The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT02050828 Org: User:
Start: 01/31/14 End: 05/31/15 Due: 05/31/16

Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT01702441 Org: User:
Start: 09/30/12 End: 12/31/14 Due: 12/31/15

Study to Assess the Absorption, Metabolism, Excretion and Pharmacokinetics of [14C]-AKB-9778

Phase: N/A Priority: Normal
NCT ID: NCT02858271 Org: User:
Start: 07/31/16 End: 07/31/16 Due: 07/31/17

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Phase: N/A Priority: Normal
NCT ID: NCT04284514 Org: User:
Start: 05/02/19 End: 12/15/19 Due: 12/15/20

Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO

Phase: N/A Priority: Normal
NCT ID: NCT02387788 Org: User:
Start: 01/31/15 End: 04/30/17 Due: 04/30/18